Previous 10 | Next 10 |
IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...
2023-07-05 17:32:16 ET Gainers: Cardlytics, Inc. ( NASDAQ: CDLX ) +9% . Autolus Therapeutics ( AUTL ) +5% . Omeros ( OMER ) +4% . Arrival ( ARVL ) +3% . Nkarta ( NKTX ) +3% . Losers: IDEAYA Biosciences ( IDYA ...
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy PR Newswire Eye preservation reported for the first UM patient treated with darovasertib monotherapy under the amended IST protocol enabli...
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types PR Newswire Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types –...
2023-06-08 17:27:08 ET Summary Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pipeline of drug candidates based on its focus on synthetic lethality. An investment analysis follo...
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , May 30, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...
IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors PR Newswire IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid...
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma PR Newswire Amended clinical trial collaboration and supply agreements with ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is the focus of IBN's latest stock spotlight. The company's shares have moved -4.37% on the day to $21.46. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted t...
2023-05-09 08:47:22 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q1 GAAP EPS of -$0.49 beats by $0.03 . Revenue of $7.88M (-30.6% Y/Y) beats by $2.5M . For further details see: IDEAYA Biosciences GAAP EPS of -$0.49 beats by $0.03, revenue of $7.8...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...